Latest news with #PeterByrne
The Irish Sun
a day ago
- Sport
- The Irish Sun
‘Life & soul of the dressing room' – Heartbreaking football team tribute to teen who died in Carlow swimming tragedy
A CARLOW football team has paid emotional tribute to "beloved" teen Peter Byrne who tragically died in a swimming incident. The young player for New Oak FC passed away after getting into difficulty in the water at Cloghristick, Milford, Co Advertisement The emergency services, including the ambulance, fire brigade and Peter is believed to have been swimming with friends when he got into difficulty in the river in the Milford area of the county - around eight kilometres from The teen, who had just finished Transition Year in the local CBS secondary It's believed that they then decided to go swimming. Advertisement Read more in News And the student's friend saw him get into difficulty in the water and tried to help him. New Oak FC took to They wrote on "Peter was a pocket rocket in the team over the last number of years. Advertisement MOST READ IN THE IRISH SUN Breaking Exclusive Exclusive "Small in stature but big in personality. He was a huge character with a touch of Roy Keane about him, not afraid of anything or anyone." They continued: "Peter was the life and soul of the dressing room and training and will be sadly missed by his coaches Ernie, Danny and all his teammates who have not only lost a fellow player but a friend. Five people killed in 48 hours on Irish roads as Gardai issue safety appeal after telling 'dreaded news' to families "On behalf of everyone at New Oak FC we would like to offer our deepest condolences to Peter's family and friends. "Our thoughts and prayers are with all who loved him. May Peter's gentle soul Rest in Peace." Advertisement The local community was also left devastated by the news of his sad passing, with a few taking to the comments section to express their condolences. One person said: "What heartbreaking and awful news, may he rest in peace. Sincere condolences to his family, friends and also your club." Someone else wrote: "So sorry to all Peter's family, friends and teammates. I can't begin to imagine how you all must be feeling. 'GREAT PLAYER' "Thinking of you all at this sad time. He was a great player, may Peter rest in peace." Advertisement A third wrote: "Condolences to all his teammates, may his gentle soul Rest in Eternal Peace, Forever Young." Mayor of Carlow Fintan Phelan described it as a 'terrible incident' and said he was 'shocked and saddened' by what had occurred. He sent his sympathies to the young man's family and also the friends who witnessed the tragedy. The Advertisement 'My thoughts are with them all at this incredibly difficult time and my thoughts are also with his friends who were there when this terrible incident happened. Look, it's a sad and difficult time for them all.' In a statement yesterday a Garda spokesperson said: "Following a search operation involving Gardai and emergency services, the Garda Water Unit recovered the body of a male, aged in his late teens, from the River Barrow at Milford, Co. Carlow, yesterday evening, Tuesday 17th June 2025. "His remains have been transferred to Waterford University Hospital where a postmortem examination will take place in due course. A file will be prepared for the Coroner." No funeral arrangements have been made as yet. Advertisement 1 Peter Byrne passed away after getting into difficulty in the water on Tuesday evening Credit: SOCIAL MEDIA COLLECT
Glasgow Times
2 days ago
- Health
- Glasgow Times
How do the new antibody drugs for Alzheimer's disease work?
– What are the medicines? Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer's. They represent a huge step forward in research because they target a known cause of the disease, rather than just treating the symptoms. Both drugs bind to amyloid, a protein which builds up in the brains of people living with Alzheimer's disease. By binding to amyloid, the drugs are designed to help clear the build-up and slow down cognitive decline. – How effective are they? Donanemab has been shown in clinical trials to slow the rate at which memory and thinking get worse by more than 20%. Evidence suggests that people get the most benefit if they are given the treatment earlier in the disease. Results show a slowing in the decline of tasks such as managing money (Dominic Lipinski/PA) Results also suggest the drug leads to a 40% slowing in the decline of everyday activities such as driving, enjoying hobbies and managing money. Lecanemab has also been shown to successfully remove protein build-up from the brains of people living with early Alzheimer's disease. For people taking lecanemab, this meant the decline in their thinking and memory skills was slowed down by 27%. It also slowed down the decline in quality of life by up to 56%. – How are the drugs given? Donanemab, developed by the pharmaceutical company Lilly, is given to patients via an intravenous drip once every four weeks. Lecanemab, developed by Eisai, is also given this way but fortnightly. – Are there any side-effects? Side-effects of the drugs can be serious and people undergo monitoring to check for them. In one clinical trial published in the Journal of the American Medical Association (JAMA) in 2023, 24% of people receiving donanemab had side-effects including brain swelling and infusion-related reactions. Four people died during the trial, with their deaths thought to be related to the drug's side-effects. Results suggest donanemab leads to a 40% slowing in the decline of everyday activities (Peter Byrne/PA) Lecanemab resulted in infusion-related reactions in around 26% of people on the trial and followed up, while 14% suffered amyloid-related imaging abnormalities causing brain swelling. Others suffered minor bleeds picked up on scans. Around one in 10 people suffered headaches, according to updated results published in May 2024. Overall, four deaths during the follow-up period were thought to be due to treatment. – How much do the drugs cost? NHS England published a briefing paper last year suggesting the cost of bringing the drugs to the health service could be £500 million to £1 billion per year. Around 50%-60% of the total estimated cost relates to the drug price, with remaining cash spent on patient assessment, diagnosis and administering the treatment. – How many people in England might the drugs have worked for? NHS England estimated between 50,000 and 280,000 patients could be eligible for the new treatments if they were approved for the NHS. To get the drugs, patients need a baseline MRI scan and then either a PET-CT scan or lumbar puncture to confirm Alzheimer's. It is possible that blood tests will be available in the future to diagnose the disease, so NHS England did warn there should be caution about driving a 'massive expansion' in other diagnostics which could become redundant in the longer term. -What do scientists think? Scientists and doctors have been divided on whether the drugs represent a real clinical benefit that is noticeable in patients day-to-day. Some argue the drugs represent a huge advance and people should be given the chance to try them. But others say the benefits are too small. Jennifer Keen, associate director of evidence, policy and influencing at the Alzheimer's Society, has said: 'we remain at an important and exciting moment', adding: 'There are currently 182 active clinical trials for Alzheimer's disease… We are on the cusp of major scientific breakthroughs beginning to improve the outlook for those with the disease.' Professor Rob Howard, from University College London, said: 'Nobody should be surprised that Nice have confirmed their earlier view that the new Alzheimer's disease treatments would not be cost-effective if used within the NHS. 'Well-conducted clinical trials demonstrated that the actual size of benefits experienced by patients were too small to be noticeable, treatment carries risks of side-effects, and the annual cost of the drugs and safety monitoring required would have been close to the cost of a nurse's salary for each treated patient. We need better treatments that can make an appreciable difference to the lives of people with dementia and these can only come from further research and study.'
Western Telegraph
2 days ago
- Health
- Western Telegraph
How do the new antibody drugs for Alzheimer's disease work?
– What are the medicines? Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer's. They represent a huge step forward in research because they target a known cause of the disease, rather than just treating the symptoms. Both drugs bind to amyloid, a protein which builds up in the brains of people living with Alzheimer's disease. By binding to amyloid, the drugs are designed to help clear the build-up and slow down cognitive decline. – How effective are they? Donanemab has been shown in clinical trials to slow the rate at which memory and thinking get worse by more than 20%. Evidence suggests that people get the most benefit if they are given the treatment earlier in the disease. Results show a slowing in the decline of tasks such as managing money (Dominic Lipinski/PA) Results also suggest the drug leads to a 40% slowing in the decline of everyday activities such as driving, enjoying hobbies and managing money. Lecanemab has also been shown to successfully remove protein build-up from the brains of people living with early Alzheimer's disease. For people taking lecanemab, this meant the decline in their thinking and memory skills was slowed down by 27%. It also slowed down the decline in quality of life by up to 56%. – How are the drugs given? Donanemab, developed by the pharmaceutical company Lilly, is given to patients via an intravenous drip once every four weeks. Lecanemab, developed by Eisai, is also given this way but fortnightly. – Are there any side-effects? Side-effects of the drugs can be serious and people undergo monitoring to check for them. In one clinical trial published in the Journal of the American Medical Association (JAMA) in 2023, 24% of people receiving donanemab had side-effects including brain swelling and infusion-related reactions. Four people died during the trial, with their deaths thought to be related to the drug's side-effects. Results suggest donanemab leads to a 40% slowing in the decline of everyday activities (Peter Byrne/PA) Lecanemab resulted in infusion-related reactions in around 26% of people on the trial and followed up, while 14% suffered amyloid-related imaging abnormalities causing brain swelling. Others suffered minor bleeds picked up on scans. Around one in 10 people suffered headaches, according to updated results published in May 2024. Overall, four deaths during the follow-up period were thought to be due to treatment. – How much do the drugs cost? NHS England published a briefing paper last year suggesting the cost of bringing the drugs to the health service could be £500 million to £1 billion per year. Around 50%-60% of the total estimated cost relates to the drug price, with remaining cash spent on patient assessment, diagnosis and administering the treatment. – How many people in England might the drugs have worked for? NHS England estimated between 50,000 and 280,000 patients could be eligible for the new treatments if they were approved for the NHS. To get the drugs, patients need a baseline MRI scan and then either a PET-CT scan or lumbar puncture to confirm Alzheimer's. It is possible that blood tests will be available in the future to diagnose the disease, so NHS England did warn there should be caution about driving a 'massive expansion' in other diagnostics which could become redundant in the longer term. -What do scientists think? Scientists and doctors have been divided on whether the drugs represent a real clinical benefit that is noticeable in patients day-to-day. Some argue the drugs represent a huge advance and people should be given the chance to try them. But others say the benefits are too small. Jennifer Keen, associate director of evidence, policy and influencing at the Alzheimer's Society, has said: 'we remain at an important and exciting moment', adding: 'There are currently 182 active clinical trials for Alzheimer's disease… We are on the cusp of major scientific breakthroughs beginning to improve the outlook for those with the disease.' Professor Rob Howard, from University College London, said: 'Nobody should be surprised that Nice have confirmed their earlier view that the new Alzheimer's disease treatments would not be cost-effective if used within the NHS. 'Well-conducted clinical trials demonstrated that the actual size of benefits experienced by patients were too small to be noticeable, treatment carries risks of side-effects, and the annual cost of the drugs and safety monitoring required would have been close to the cost of a nurse's salary for each treated patient. We need better treatments that can make an appreciable difference to the lives of people with dementia and these can only come from further research and study.'
Sunday World
2 days ago
- Sunday World
Teen who died swimming in Carlow is named – ‘No words can express the pain'
Peter Byrne tragically died after getting into difficulty while swimming in the River Barrow on Tuesday evening A teenage boy who tragically died after getting into difficulty while swimming in the River Barrow in Co Carlow yesterday has been named locally as Peter Byrne. The 17-year-old was in the water at Cloghristick, Milford in Co Carlow with his two friends, also aged in their teens, when he got into difficulty and went under the water. The alarm was raised at 6.30pm on Tuesday and emergency services including ambulance, fire brigade, gardaí and the Garda Water Unit rushed to the scene and a search for the teenager began. The young man's body was recovered at 11.30pm last night by divers from the Garda Water Unit within a 10m radius of where he was last seen. Peter was from Carlow Town and was very well-known and much-loved in the area having played with the local soccer club New Oak F.C. Principal of St Mary's Academy CBS in Carlow Town, Fiona Lennon, said "no words can express the pain of such a loss". "We learned this morning of the death of one our past pupils, Peter Byrne," Ms Lennon said. "Our school and our community are deeply saddened by this tragedy and we are particularly mindful of Peter's family and friends at this time. Their grief is heavy and we hold them in our thoughts as they navigate these difficult days. The late Peter Byrne "No words can express the pain of such a loss and we extend to them our deepest sympathies and support. "We will take time in the coming days to reflect and remember Peter and we ask you to keep his beloved family in your thoughts and prayers." Mayor of Carlow, Cllr Fintan Phelan, said his thoughts are with Peter's family and also his friends who witnessed the tragedy. "I want to extend my deepest sympathies to the young man's family," said Cllr Phelan. "My thoughts are with them all at this incredibly difficult time and my thoughts are also with his friends who were there when this terrible incident happened. It is a very, very sad and difficult time for them all." Meanwhile principal of St. Joseph's NS in Carlow, Cllr Fergal Browne, paid tribute to Peter, who attended the school as a young child. "As both a councillor in Carlow and the principal of St Joseph's, a school which Peter was a former student of, I would like to extend my deepest sympathies to his family at this terrible time. "It is an awful tragedy, especially to lose someone so young." The late Peter Byrne News in 90 Seconds - June 18th Since the tragic news broke this morning, Peter's friends have taken to social media to share their heartbreak and remember a young man who was only starting out in life. "Rest in eternal peace Peter," wrote one friend on social media. "It was a honour knowing and growing up with you as a child. May God watch over your family at this devastating and hard time. "You've broken everyone's hearts Peter. You were one-of-a-kind, a true gentleman and a kind and caring soul. May you get the best bed up there, praying for your family at this hard time. You'll be missed big time. Rest easy kid forever 17. Gone but never forgotten." "May this true gentleman of a chap at that young age be given the best bed up there, you deserve it," added another friend on social media. "Gone but never forgotten. Rest in paradise Peter." Gardaí say Peter's death is being treated as a "tragic incident". His remains have since been brought to Waterford University Hospital where a post-mortem examination will be carried out in due course. A file is also being prepared for the coroner.
Irish Times
2 days ago
- Irish Times
Friend ‘tried to help him to safety': Boy (17) who drowned in river Barrow named locally
A teenage boy who died after getting in difficulty swimming in the river Barrow on Tuesday evening has been named locally. Peter Byrne, from Dolmen Gardens, Carlow town was found by garda divers around 11pm in the river Barrow. The 17-year-old is understood to have been swimming with a friend when he got into difficulty around 6.30pm in the river in the Milford area of the county. The teenager had been at a local gym with a couple of friends when he and another friend decided to go swimming at Cloghristick, Milford. READ MORE However, it's understood he got into difficulty at the swimming spot due to strong river currents. His friend saw what was happening and desperately tried to help him. However, he too was being drawn into the river currents but managed to swim to safety and raise the alarm. Gardaí and emergency services from Carlow town were quickly on the scene. The teenager was a transition year student in the local CBS secondary school in Carlow town. Emergency services along with gardaí remained at the scene for several hours as a search got under way to locate the teenager. The scene remains cordoned off by gardaí. In a statement gardaí said that following a search operation involving emergency services, the Garda Water Unit recovered the body of a male, aged in his late teens, from the river Barrow at Milford, yesterday evening. The teenager's remains have been transferred to University Hospital Waterford (UHW) where a postmortem examination will take place in due course. A file will be prepared for the Coroner. A local man who knows the Byrne family said: 'It's an awful shock to hear such news. The family are well-known in the area. Both of Peter's friends, the boy who tried to help him to safety in the water and their friend who was at the gym with them, are both in a terrible state.'
